Electroencephalography-derived biomarkers of antidepressant response

Harvard Review of Psychiatry

Volumn 19, Issue 3, 2011, Pages 144-154

  Iosifescu, Dan Vlad ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; EEG source localization; electroencephalography; event related potentials; major depressive disorder; predictor; quantitative electroencephalography; response

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; PAROXETINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ACCURACY; ALPHA RHYTHM; ANTERIOR CINGULATE; ANTIDEPRESSANT TREATMENT RESPONSE INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; FRONTAL CORTEX; GENETIC POLYMORPHISM; HAMILTON SCALE; HEMISPHERIC DOMINANCE; HUMAN; LEFT HEMISPHERE; LOW RESOLUTION BRAIN ELECTROMAGNETIC TOMOGRAPHY; MAGNETOENCEPHALOGRAPHY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PREDICTION; PREDICTIVE VALUE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RESTING STATE ELECTROENCEPHALOGRAPHY; REVIEW; RIGHT HEMISPHERE; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; THETA RHYTHM; TREATMENT PLANNING; TREATMENT RESPONSE;

ALPHA RHYTHM; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BRAIN; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; PREDICTIVE VALUE OF TESTS; THETA RHYTHM; TREATMENT OUTCOME;

EID: 79958050956     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2011.586549     Document Type: Review

References (65)

1. Rush AJ, Kraemer HC, Sackeim HA, et al.; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841-53.
2. Trivedi M, Rush A,Wisniewski S, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40. (Pubitemid 43050100)
3. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010;79:267-79.
4. Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry 2006;67:1226-31. (Pubitemid 44439694)
5. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700. (Pubitemid 28364385)
6. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-51. (Pubitemid 351704490)
7. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004;291:1887-96. (Pubitemid 38509503)
8. Iosifescu DV. Treating depression in themedically ill. Psychiatr Clin North Am 2007;30:77-90.
9. Esposito K, Goodnick P. Predictors of response in depression. Psychiatr Clin North Am 2003;26:353-65. (Pubitemid 36583568)
10. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-14.
11. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8:1057-61. (Pubitemid 27152174)
12. Canli T, Cooney RE, Goldin P, et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 2005;16:1267-70. (Pubitemid 41225193)
13. Towle VL, Bolaños J, Suarez D, et al. The spatial location of EEG electrodes: locating the best-fitting sphere relative to cortical anatomy. Electroencephalogr Clin Neurophysiol 1993;86:1-6. (Pubitemid 23023919)
14. Ulrich G, Renfordt E, Zeller G, Frick K. Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question. Pharmacopsychiatry 1984;17:178-83. (Pubitemid 15213945)
15. Ulrich G, Haug HJ, Stieglitz RD, Fahndrich E. EEG characteristics of clinically defined on-drug-responders and nonresponders-a comparison clomipramine vs.maprotiline. Pharmacopsychiatry. 1988;21:367-8. (Pubitemid 19024185)
16. Ulrich G, Haug HJ, Fahndrich E. Acute vs. chronic EEG effects in maprotiline-and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord 1994;32:213-7.
17. Knott VJ, Telner JI, Lapierre YD, Browne M, Horn ER. Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord 1996;39:175-84. (Pubitemid 26291783)
18. Knott V, Mahoney C, Kennedy S, Evans K. Pre-treatment EEG and its relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry 2000;33:201-5.
19. Bruder GE, Stewart JW, Tenke CE, et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry 2001;49:416-25. (Pubitemid 32234304)
20. Bruder GE, Sedoruk JP, Stewart JW, McGrath PJ, Quitkin FM, Tenke CE. Electroencephalographs alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre-and posttreatment findings. Biol Psychiatry 2008;63:1171-7. (Pubitemid 351734498)
21. Feenstra BW, Holsheimer J. Dipole-like neuronal sources of theta rhythm in dorsal hippocampus, dentate gyrus and cingulated cortex of the urethaneanesthetized rat. Electroencephalogr Clin Neurophysiol 1979;47:532-8. (Pubitemid 10238996)
22. Ishii R, Shinosaki K, Ukai S, et al. Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 1999;10:675-9. (Pubitemid 29393804)
23. Asada H, Fukuda Y, Tsunoda S, Yamaguchi M, Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett 1999;274:29-32. (Pubitemid 29458971)
24. Heikman P, Salmelin R, Makela JP, Hari R, Katila H, Kuoppasalmi K. Relation between frontal 3-7 Hz MEG activity and the efficacy of ECT in major depression. J ECT 2001;17: 136-40. (Pubitemid 32545785)
25. Iosifescu DV, Greenwald S, Devlin P, et al. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharm 2009;19:772-7.
26. Spronk D, Arns M, Barnett KJ, Cooper NJ, Gordon E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J Affect Disord 2011; 128:41-8.
27. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res 2009;169:124-31.
28. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 2009;169:132-8.
29. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res 1999;90:125-40. (Pubitemid 29256142)
30. Leuchter A, Cook I, Uijtdehaage S, et al. Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 1997;58 suppl 16:22-31. (Pubitemid 28049099)
31. Cook I, Leuchter A. Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 2001;6:113-20.
32. Cook I, Leuchter A, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002;27:120-31. (Pubitemid 34626748)
33. Leuchter A, Cook I, Witte E, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159:122-9. (Pubitemid 41070737)
34. Cook I, Leuchter A, Morgan M, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res 2005;39:461-6. (Pubitemid 40909989)
35. Bares M, Brunovsky M, Kopecek M, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res 2007;41:319-25. (Pubitemid 44854994)
36. Bares M, Brunovsky M, Kopecek M, et al. Early reduction in prefrontal thetaQEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry 2008;23:350-5.
37. Leuchter AF, Cook IA, Lufkin RB, et al. Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1994;1:208-19. (Pubitemid 24253436)
38. Suffin SC, Emory WH. Neurometric subgroups in attentional and affective disorders and their association with pharmacotherapeutic outcomes. Clin Electroencephalography 1995;26:76-83.
39. Debattista C, Kinrys G,Hoffman D, et al. The use of referenced-EEG (rEEG) in assistingmedication selection for the treatment of depression. J Psychiatr Res 2011;45:64-75.
40. Suffin SC, Emory WH, Gutierrez G, Arora G, SchillerMJ, Kling A. A QEEG database method for predicting pharmacotherapeutic outcome in refractory major depressive disorders. J Am Physicians Surg 2007;12:104-8.
41. DeBattista C, Hoffman D, Schiller M, Iosifescu D. Referenced-EEG (rEEG) guidance of medications for treatment resistant depressed patients-a pilot study. Poster no. 228. U.S. Psychiatric and Mental Health Congress, San Diego, CA, Oct 2008.
42. O'Donnell BF, McCarley RW, Potts GF, et al. Identification of neural circuits underlying P300 abnormalities in schizophrenia. Psychophysiology 1999;36:388-98. (Pubitemid 29237439)
43. Bruder GE, Tenke CE, Stewart JW, et al. Brain event-related potentials to complex tones in depressed patients: relations to perceptual asymmetry and clinical features. Psychophysiology 1995;32:373-81.
44. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999;56:713-8. (Pubitemid 29357732)
45. Hegerl U, Gallinat J, Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 2001;62:93-100. (Pubitemid 32126614)
46. O'Neill BV, Croft RJ, Nathan PJ. The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings. Hum Psychopharmacol 2008;23:355-70.
47. Paige SR, Fitzpatrik DF, Kline JP, Balogh SE, Hendricks SE. Event-related potential (ERP) amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 1994;30:197-201. (Pubitemid 24350939)
48. Paige SR, Hendricks SE, Fitzpatrick DF, Balogh S, Burke WJ. Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull 1995;31:243-8.
49. Lee TW, Yu YW, Chen TJ, Tsai SJ. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. J Psychiatry Neurosci 2005;30:202-5. (Pubitemid 40942459)
50. Gallinat J, Bottlender R, Juckel G, et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 2000;148:404-11. (Pubitemid 30169759)
51. Linka T, Muller BW, Bender S, Sartory G, Gastpar M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry 2005;38:139-43. (Pubitemid 40965968)
52. Juckel G, Pogarell O, Augustin H, et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry 2007;68:1206-12. (Pubitemid 47395622)
53. Mulert C, Juckel G, Brunnmeier M, et al. Prediction of treatment response in major depression: integration of concepts. J Affect Disord 2007;98:215-25. (Pubitemid 46149060)
54. Linka T, Sartory G, Wiltfang J, Müller BW. Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression. Neurosci Lett 2009;463:26-30.
55. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001;158:405-15. (Pubitemid 32205197)
56. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011;36:183-206.
57. Mulert C, Juckel G, Brunnmeier M, et al. Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clin EEG Neurosci 2007; 38:78-81. (Pubitemid 46866506)
58. Korb AS, Hunter AM, Cook IA, Leuchter AF. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol 2009;120:1313-9.
59. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol 1994;18:49-65. (Pubitemid 24344515)
60. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci 2009;11:435-46.
61. Leuchter AF, Cook IA, Hunter A, Korb A. Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence. Clin EEG Neurosci 2009;40:78-83.
62. Friedman ES, Wisniewski SR, Gilmer W, et al. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. Depress Anxiety 2009;26:612-21.
63. Hunter AM, Leuchter AF, Morgan ML, et al. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005;30:792-9. (Pubitemid 40397086)
64. Iosifescu DV, Greenwald S, Devlin P, et al. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand 2008;117:271-6. (Pubitemid 351347466)
65. Hunter AM, Leuchter AF, Cook IA, AbramsM. Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. Acta Psychiatr Scand 2010;122:461-9.